Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 386 plus paclitaxel and carboplatin as first-line treatment for advanced ovarian, primary peritoneal, or fallopian tube cancer
NL-OMON41365Phase 3Active, not recruiting
- Sponsor
- Amgen
- Start
- Apr 2012
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of trebananib in epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by Amgen. Started Apr 2012; status: active, not recruiting.
02
Drugs
trebananib
03
Conditions
epithelial ovarian cancer (EOC)primary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NL-OMON41365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41365.